business

Merck and Moderna Shares Rise Following Successful Melanoma Vaccine Trial

19 Ağustos 2026Bloomberg

Shares of Moderna and Merck experienced a significant increase following positive results from a late-stage trial of their mRNA vaccine aimed at combating melanoma. The study indicated that the vaccine effectively reduced the recurrence of this skin cancer.
This development has sparked optimism in the biotech sector regarding the potential of mRNA technology in cancer treatment.
The success of this melanoma trial comes at a time when the medical community is increasingly exploring innovative treatments for cancer, particularly using cutting-edge technologies like mRNA. Both companies have been at the forefront of vaccine development during the COVID-19 pandemic, and this new application cou…
The soaring stock prices of Moderna and Merck reflect investor confidence in the efficacy of mRNA vaccines beyond infectious diseases. This trial's success could mark a pivotal moment in cancer immunotherapy, potentially paving the way for broader applications of mRNA technology in oncology.

NewsAI özeti

This article is for informational purposes only and does not constitute investment advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.